Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
9.49
+0.16 (1.71%)
Feb 6, 2026, 4:00 PM EST - Market closed
Valneva SE Revenue
Valneva SE had revenue of 29.41M EUR in the quarter ending September 30, 2025, a decrease of -35.82%. This brings the company's revenue in the last twelve months to 179.91M, up 13.48% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
179.91M EUR
Revenue Growth
+13.48%
P/S Ratio
3.92
Revenue / Employee
257,017 EUR
Employees
700
Market Cap
826.79M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | 7.74M | 7.35% |
| Dec 31, 2017 | 105.29M | 7.40M | 7.56% |
| Dec 31, 2016 | 97.89M | 14.56M | 17.47% |
| Dec 31, 2015 | 83.33M | 40.91M | 96.41% |
| Dec 31, 2014 | 42.43M | 6.44M | 17.89% |
| Dec 31, 2013 | 35.99M | 326.00K | 0.91% |
| Dec 31, 2012 | 35.67M | 2.78M | 8.46% |
| Dec 31, 2011 | 32.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 312.30M |
| Maravai LifeSciences Holdings | 192.44M |
| Geron | 183.40M |
| Xencor | 150.13M |
| Janux Therapeutics | 10.00M |
| YD Bio | 510.36K |
VALN News
- 1 day ago - VALNEVA Declaration of shares and voting rights: January 31, 2026 - GlobeNewsWire
- 4 days ago - Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 19 days ago - Valneva withdraws application for standard US approval of its chikungunya shot - Reuters
- 19 days ago - Valneva Provides Update on Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 4 weeks ago - Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Valneva SE - Declaration of voting rights - December 2025 - GlobeNewsWire
- 5 weeks ago - Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement - GlobeNewsWire
- 2 months ago - Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® - GlobeNewsWire